Osteosarcoma Research Portal logoOsteosarcoma Research Portal

Regorafenib (Stivarga)

. Draft fact sheet, awaiting Henry's approval. Items marked [check] must be verified before publishing.

← All drugs · Search the portal

Facts

Topic Fact Source (access date)
First approval US 27 Sep 2012 (Bayer); EU 26 Aug 2013; China Dec 2017 (liver cancer; colorectal and GIST earlier in 2017); about 14 years Drugs@FDA via openFDA, https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA203085 (accessed 4 Nov 2026); EMA medicines report, https://www.ema.europa.eu/en/documents/report/medicines-output-medicines-report_en.xlsx (accessed 4 Nov 2026); Bayer https://www.bayer.com/media/en-us/bayer-receives-approval-in-china-for-stivargar-regorafenib-for-the-second-line-systemic-treatment-of-liver-cancer/ (4 Nov 2026)
Mechanism Tablet that blocks several kinases (VEGFR1-3, TIE2, KIT, RET, RAF, PDGFR, FGFR) involved in blood vessel growth and cell growth Bayer page above
Use in osteosarcoma Relapsed or progressing disease, adults; NCCN category 1 second line (secondary source); listed in Chinese paediatric guideline; UK compassionate access only NCCN via secondary source https://www.cancertherapyadvisor.com/ddi/bone-cancer-treatment-pharmacologic-management/ (accessed 31 Oct 2026; primary NCCN not opened); CSCO guideline and 2026 Chinese paediatric guideline, via /workspace/osteo-videos/level2/treatment_by_country.md (accessed 31 Oct 2026); UK bone sarcoma guidelines 2024, https://pmc.ncbi.nlm.nih.gov/articles/PMC11723950/ (accessed 3 Nov 2026)
Combined with Used alone in trials; REGOMAIN tests maintenance after relapse (NCT04698785) entries.json (portal export), sources opened 31 Oct to 3 Nov 2026
Results SARC024 (ages 18-76): median PFS 3.6 v 1.7 months, HR 0.42. REGOBONE: placebo-controlled, non-comparative design doi:10.1200/JCO.18.02374; doi:10.1016/S1470-2045(18)30742-3 (3 Nov 2026)
Side effects Hand-foot skin reaction, high blood pressure, tiredness, diarrhoea, infection, bleeding; US boxed warning for severe and sometimes fatal liver damage openFDA label API, https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22Stivarga%22 (accessed 4 Nov 2026) (set id 824f19c9-0546-4a8a-8d8f-c4055c04f7c7)
Owner Bayer (originator and marketer); in patent; no EU generic in EMA list EMA medicines report, https://www.ema.europa.eu/en/documents/report/medicines-output-medicines-report_en.xlsx (accessed 4 Nov 2026)
Regulatory US, EU, UK, China: approved for colorectal cancer, GIST, liver cancer; not osteosarcoma entries.json (portal export), sources opened 31 Oct to 3 Nov 2026; Bayer page

Hypotheses and open points (not established fact)